Loading organizations...
§ Private Profile · Sydney, New South Wales, Australia
Clinical-stage biopharmaceutical company developing the EDV nanocell platform for targeted delivery of cancer therapeutics in oncology.
Based in Sydney, Australia, and New York, United States, EnGeneIC is a clinical-stage biopharmaceutical company that develops a bacterially-derived nanoparticle platform for the targeted delivery of cancer therapeutics. The firm utilizes its proprietary EnGeneIC Dream Vector technology to deliver chemotherapeutics, siRNA, and miRNA directly into tumor cells, aiming to minimize systemic toxicity while simultaneously stimulating the body's anti-tumor immune responses. To support its ongoing Phase-2 clinical trials targeting difficult-to-treat oncology indications, the enterprise successfully secured $10 million in Series B financing and previously exceeded its pre-IPO equity crowdfunding target by 500 percent. The company's venture financing rounds have been backed by institutional investors including GRT Capital Partners LLC and Foley Ventures LLC, with corporate development leadership previously featuring executive Anjan Chatterji. EnGeneIC was officially founded in 2001 by Jennifer MacDiarmid and Himanshu Brahmbhatt.
EnGeneIC has raised $10.0M across 1 funding round.
EnGeneIC has raised $10.0M in total across 1 funding round.
EnGeneIC has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Series B in January 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 6, 2015 | $10M Series B | GRT Capital Partners | Foley Ventures | Announced |
EnGeneIC has raised $10.0M in total across 1 funding round.
EnGeneIC's investors include GRT Capital Partners, Foley Ventures.